Afatinib is a good and irreversible EGFR TKI, and recently, many clinical trials have proved that it can effectively prolong the median PFS and OS time in NSCLC patients when compared to the first-generation EGFR TKIs [19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.